UCART123 was effective in eliminating AML both in vivo and in vitro without significant effects on normal cells.99 A phase I/II clinical trial on autologous anti–CLL-1 CAR-T cells showed that of 8 children with R/R AML, 4 achieved morphologic leukemia-free status without minimal residual disease, and 1 achieved CR.100 Wu et al reported a preclinical study on anti-CD70 CAR-T cells in AML, demonstrating potent cytotoxicity when cultured with CD70+ AML cell lines and potent anti-leukemic activity in a mouse model. Here, CD70 is linked to B-cell chronic lymphocytic leukemia.